Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01690221
Other study ID # VEN307-AF-001
Secondary ID
Status Completed
Phase Phase 3
First received September 17, 2012
Last updated January 22, 2014
Start date October 2012
Est. completion date January 2014

Study information

Verified date January 2014
Source Ventrus Biosciences, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if the study drug, VEN307 (diltiazem hydrochloride cream) is safe and to see if it will help with treatment of pain associated with anal fissures.


Description:

Primary Objective:

To evaluate the efficacy of diltiazem hydrochloride cream on reduction of worst anal fissure (AF)-related pain associated with or following defecation when administered three times a day (TID) for 28 days.


Recruitment information / eligibility

Status Completed
Enrollment 434
Est. completion date January 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Males or females, aged = 18 to = 75 years.

2. Subjects with evidence of a circumscribed fissure, with induration at the edges.

3. Subjects with AF-related pain associated with or following defecation occurring at least 2 times a week for at least 28 days prior to signing the informed consent form (ICF).

4. AF-related pain associated with or following defecation of at least 5 on an 11-point numerical rating score scale (NRS) at the last defecation prior to signing the ICF (0 being no pain; 10 being the worst possible pain).

5. Average AF-related pain associated with or following defecation of at least 5 on an 11-point NRS during the last 3 days in which subject had a defecation during the 7 days prior to randomization.

6. Any female of non-childbearing potential, including any female who: a) has had a hysterectomy, b) has had a bilateral oophorectomy, c) has had a bilateral tubal ligation or d) is post menopausal (demonstration of total cessation of menses for = 1 year from the date of screening visit).

7. Females of child bearing potential who agree to use at least one form of contraception (may be a barrier method), during the full duration of the study.

8. Able to communicate adequately with the investigator and to comply with the requirements for the entire study.

9. Capable of using the IVRS and able to adequately communicate comprehension of the IVRS questions to the investigator.

10. Capable of and freely willing to provide written informed consent prior to participating in the study.

Exclusion Criteria:

1. Unwilling to have visual or medical examination of the AF.

2. More than 1 AF.

3. Subjects with AF associated with or caused by other conditions, including but not limited to: drug-induced, trauma, HIV infection, fistula-in-ano, inflammatory bowel disease, perianal sepsis or malignancy.

4. Unwilling to stop all other concomitant topical preparations applied in and around the anus from signing of ICF through Day 29 of the study.

5. Use of glyceryl trinitrate (GTN) ointment for 7 days (continuous or not) in the 28 days prior to signing the ICF.

6. Unwilling to discontinue use of sitz baths for up to 4 hours after each application of investigational product from signing of ICF to end of study.

7. Unwilling to discontinue use of anesthetics from signing the ICF to end of study.

8. Subfissure injection of botulinum toxin in the 3 months prior to signing the ICF.

9. Known sensitivity to investigational product(s) or calcium channel blockers.

10. Previous treatment with diltiazem hydrochloride cream or any other topical calcium channel blockers.

11. Active treatment with anti-viral therapies for HIV (e.g. indinavir, nelfinivir, ritonavir).

12. Treatment with any of the following medications within 14 days prior to signing the ICF:

- Amitriptyline

- Benzodiazepines

- ß-adrenoceptor antagonists (Beta-Blockers)

- Buspirone

- Calcium channel blockers

- Carbamazepine

- Cimetidine

- Cyclosporin

- Digoxin

- Investigational agents

- Lovastatin

- Opioids

- Pregabalin

- Quinidine

- Rifampin

13. Following concomitant disease state:

- Sick sinus syndrome except in the presence of a functioning ventricular pacemaker.

- Second-or third-degree AV block except in the presence of a functioning ventricular pacemaker.

- Hypotension (less than 90 mm Hg systolic).

- Acute myocardial infarction and pulmonary congestion documented by x-ray.

- History of bipolar disorder, psychosis, schizophrenia, mania, suicide attempt or suicidal ideation, or any other significant psychiatric illness (with the exception of intermittent anxiety) per investigator judgment.

- History of clinically significant renal disease per investigator judgment.

- History of clinically significant Alzheimer's or Parkinson's disease per investigator judgment.

- History of clinically significant hepatic disease per investigator judgment.

- Current infection treated with a macrolide antibiotic.

- Clinical evidence or history of fecal incontinence.

- Clinical evidence or history of anal fistula.

- Clinical evidence or history of anal abscess.

- History of inflammatory bowel disease (e.g. Crohn's disease, Ulcerative Colitis).

- History of any prior anal or rectal surgery including but not limited to: lateral sphincterotomy and anal stretch (with the exception of hemorrhoidal banding and laser surgery).

- Grade 4 hemorrhoids.

- Chronic constipation.

14. History of radiation therapy to the pelvis.

15. Fixed anal stenosis/fibrosis.

16. Major organ transplant.

17. Any clinically significant laboratory abnormalities during screening per investigator judgment.

18. Body Mass Index (BMI) > 40 kg/m2

19. Malignancy within 5 years prior to randomization (with the exception of treated basal cell/squamous cell carcinoma of the skin).

20. Any disease or prior/planned surgery that may interfere with the subject successfully completing the study.

21. Currently using narcotic(s).

22. Breast-feeding females.

23. Employees, family members, or students of the investigator or clinical site.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
VEN 307
VEN307 applied three times a day, in and around the anus, for 28 days.
Placebo
Placebo cream applied three times a day, in and around the anus, for 28 days.

Locations

Country Name City State
United States Investigative Clinical Research Annapolis Maryland
United States The Crawford Clinic Anniston Alabama
United States NCH Medical Group Arlington Heights Illinois
United States Morehouse School of Medicine Atlanta Georgia
United States Georgia Health Sciences University Augusta Georgia
United States Innovative Medical Research of South Florida Aventura Florida
United States University of Maryland Medical Center Baltimore Maryland
United States NW Gastroenterology Bellevue Washington
United States Bend Memorial Clinic Bend Oregon
United States Medispect Boone North Carolina
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Connecticut Clinical Research Foundation CT Gastroenterology Institute At Bristol Hospital Bristol Connecticut
United States Life Medi-Research and Management Brooklyn New York
United States Charlottesville Medical Research Charlottesville Virginia
United States Gastroenterology Associates of Tidewater Chesapeake Virginia
United States Metropolitan Gastroenterology Group, Chevy Chase Clinical Research Chevy Chase Maryland
United States South Lake Pain Institute Clermont Florida
United States Cleveland Clinic Cleveland Ohio
United States University Hospitals Case Medical Center Cleveland Ohio
United States Arrowhead Regional Medical Center Colton California
United States Gastro Center of Maryland Columbia Maryland
United States The Corvallis Clinic, Clinical Research Center Corvallis Oregon
United States Research Across America Dallas Texas
United States Dayton Gastroenterology, Inc. Dayton Ohio
United States Atlanta Center for Gastroenterology Decatur Georgia
United States Rocky Mountain Clinical Research, LLC Denver Colorado
United States Duke University Durham North Carolina
United States North Shore University Health System Evanston Illinois
United States Womack Army Medical Center Ft. Bragg North Carolina
United States Meritus Center For Clinical Research Hagerstown Maryland
United States Penn State Hershey Medical Center Hershey Pennsylvania
United States Private Practice Hollywood Florida
United States Houston Digestive Disease Clinic Houston Texas
United States Houston Endoscopy and Research Center Houston Texas
United States Research Concepts, GP LLC Houston Texas
United States University of TX Affiliated Hospitals Houston Texas
United States Indiana University School of Medicine Indianapolis Indiana
United States Kendrick Regional Medical Center Indianapolis Indiana
United States University of Iowa Hospital and Clinics Iowa City Iowa
United States CRC of Jackson Jackson Mississippi
United States HCCA Clinical Research Solutions Jackson Tennessee
United States Jefferson City Medical Group Jefferson City Missouri
United States UC San Diego La Jolla California
United States Alliance Research Centers Laguna Hills California
United States Impact Clinical Trials Las Vegas Nevada
United States Midwest Center for Clinical Research Lee's Summit Missouri
United States Axis Clinical Trials Los Angeles California
United States Cedars Sinai Los Angeles California
United States Gastrointestinal Biosciences Los Angeles California
United States University of Louisville Louisville Kentucky
United States Gastrointestinal Specialist of Georgia Marietta Georgia
United States Great Lakes Gastroenterology Mentor Ohio
United States Advance Medical Research Center Miami Florida
United States Well Pharma Medical Research Corp. Miami Florida
United States Akta Medika Miami Beach Florida
United States Medical College of Wisconsin Department of Surgery Milwaukee Wisconsin
United States Surgical Association of Mobile Mobile Alabama
United States University of South Alabama Mobile Alabama
United States Delta Research Partners Monroe Louisiana
United States West Penn Allegheny Health System Monroeville Pennsylvania
United States Montgomery Women's Health Association, PC Montgomery Alabama
United States Gastroenterology Group of Naples, PA Naples Florida
United States Vanderbilt Univ Dept of Colon and Rectal Surgery Nashville Tennessee
United States Ochsner New Orleans Louisiana
United States Colorectal Associates of NY New York New York
United States HCCA Clinical Research Solutions New York New York
United States Manhattan Surgical Associates, LLP New York New York
United States Medical Research Associates of New York (New York Gastroenterology Associates, LLP) New York New York
United States Pain Specialists of Charleston North Charleston South Carolina
United States Healthcare Clinical Data, Inc. North Miami Florida
United States Institute of Pain Research Oklahoma City Oklahoma
United States Colon and Rectal Surgery, Inc Omaha Nebraska
United States University of California - Irvine Medical Center Orange California
United States Gastroenterology Associates of Orangeburg, PA Orangeburg South Carolina
United States Private Practice Pembroke Pines Florida
United States Drexel Univ College of Medicine Philadelphia Pennsylvania
United States Temple University Physicians, Jeanes Hospital Philadelphia Pennsylvania
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania
United States Mayo Clinic - Arizona Phoenix Arizona
United States Advanced Medical Research Center Port Orange Florida
United States Westover Heights Clinic Portland Oregon
United States Premier Medical Group Poughkeepsie New York
United States Colorado Research Works Pueblo Colorado
United States University of North Carolina Raleigh North Carolina
United States Wake Research Associates Raleigh North Carolina
United States Jefferson Surgical Clinic Roanoke Virginia
United States University of Utah HSC Salt Lake City Utah
United States Digestive Care Associated, A Medical Corporation San Carlos California
United States ColoProctology Associates Seabrook Texas
United States Digestive Disease Institute, Virginia Mason Medical Center Seattle Washington
United States Baystate Medical Center Department of Surgery Springfield Massachusetts
United States Atlanta Gastroenterology Consultants Suwanee Georgia
United States Madigan Army Medical Center Tacoma Washington
United States University of South Florida, South Campus Tampa Florida
United States West Coast Clinical Research Tarzana California
United States Rocky Mountain Clinical Research, LLC Thornton Colorado
United States Center for Digestive Health Troy Michigan
United States Desert Sun Clinical Research, LLC Tucson Arizona
United States Gastroenterology Group & Endoscopy Center of South NJ (GGSJ) Vineland New Jersey
United States C&R Surgical Assoc of South Jersey Voorhees New Jersey
United States Washington Hospital Center - MedStar Health Research Institute Washington District of Columbia
United States Trial Management Associates Wilmington North Carolina
United States Florida Medical Clinic, P.A. Zephyrhills Florida

Sponsors (1)

Lead Sponsor Collaborator
Ventrus Biosciences, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline (average NRS during the last 3 days in which subject had a defecation during the 7 day screening period) in average of worst AF-related pain associated with or following defecation for Days 22-28 (Week 4). 28 days